{"id":"NCT02425644","sponsor":"Actelion","briefTitle":"Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis","officialTitle":"Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-04","primaryCompletion":"2019-05-16","completion":"2019-05-16","firstPosted":"2015-04-24","resultsPosted":"2021-06-11","lastUpdate":"2025-03-30"},"enrollment":1133,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"ponesimod","otherNames":["ACT-128800"]},{"type":"DRUG","name":"teriflunomide","otherNames":[]}],"arms":[{"label":"Ponesimod","type":"EXPERIMENTAL"},{"label":"Teriflunomide","type":"ACTIVE_COMPARATOR"}],"summary":"International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis","primaryOutcome":{"measure":"Annualized Confirmed Relapse Rate","timeFrame":"From randomization to end of study (Week 108)","effectByArm":[{"arm":"Ponesimod 20 mg","deltaMin":0.202,"sd":null},{"arm":"Teriflunomide 14 mg","deltaMin":0.29,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":162,"countries":["United States","Belarus","Bosnia and Herzegovina","Bulgaria","Canada","Croatia","Czechia","Finland","France","Georgia","Germany","Greece","Hungary","Israel","Italy","Latvia","Lithuania","Mexico","Poland","Portugal","Romania","Russia","Serbia","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38301149","37155132","36550636","36047474","33779698"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;parentIdentifier=AC-058B301&amp;attachmentIdentifier=24f4f084-9a98-4430-a172-80d455f49865&amp;fileName=AC-058B301_Additional_result_data_CH.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":565},"commonTop":["Nasopharyngitis","Alanine Aminotransferase Increased","Headache","Upper Respiratory Tract Infection","Nausea"]}}